Search

GlaxoSmithKline PLC

Închisă

SectorSănătate

1,888 -1.44

Rezumat

Modificarea prețului

24h

Curent

Minim

1887.5

Maxim

1907

Indicatori cheie

By Trading Economics

Venit

1.2B

1.8B

Vânzări

-989M

7.6B

P/E

Medie Sector

13.597

50.102

EPS

0.465

Randament dividend

3.5

Marjă de profit

24.105

Angajați

66,841

EBITDA

577M

2.8B

Recomandări

By TipRanks

Recomandări

Neutru

Prognoză pe 12 luni

+8.57% upside

Dividende

By Dow Jones

Randament dividend

Medie Sector

3.50%

2.33%

Următoarele câștiguri

28 iul. 2026

Data viitoare de dividende

9 iul. 2026

Următoarea dată ex-dividende

13 aug. 2026

Statistici piață

By TradingEconomics

Capitalizare de piață

-3B

77B

Deschiderea anterioară

1889.44

Închiderea anterioară

1888

Sentimentul știrilor

By Acuity

36%

64%

101 / 344 Clasament în Healthcare

GlaxoSmithKline PLC Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

29 apr. 2026, 06:42 UTC

Câștiguri

GSK Earnings Boosted by Higher Specialty Medicine Sales

29 mai 2026, 09:17 UTC

Market Talk

GSK Hepatitis B Drug Data Beat Expectations -- Market Talk

6 mai 2026, 13:35 UTC

Market Talk

GSK Is Taking Steps in Right Direction, But Might Need More -- Market Talk

29 apr. 2026, 10:39 UTC

Market Talk
Achiziții, Fuziuni, Preluări

GSK CEO Sees RAPT Therapeutics Acquisition as Template for Future Deals -- Market Talk

29 apr. 2026, 10:06 UTC

Market Talk
Câștiguri

AstraZeneca, GSK Results Fail to Impress Market -- Market Talk

29 apr. 2026, 10:02 UTC

Market Talk
Câștiguri

GSK Makes Ideal Start for New CEO -- Market Talk

29 apr. 2026, 06:07 UTC

Câștiguri

GSK PLC Sees 70p 2026 Dividend Payout

29 apr. 2026, 06:07 UTC

Câștiguri

GSK PLC Declares Dividend of 17p

29 apr. 2026, 06:07 UTC

Câștiguri

GSK PLC Free Cash Flow of GBP0.8B

29 apr. 2026, 06:06 UTC

Câștiguri

GSK PLC Cash Generated From Operations GBP1.4B

29 apr. 2026, 06:06 UTC

Câștiguri

GSK PLC 1Q General Medicines Sales GBP2.3B

29 apr. 2026, 06:06 UTC

Câștiguri

GSK PLC 1Q Vaccines Sales GBP2.1B

29 apr. 2026, 06:06 UTC

Câștiguri

GSK PLC 1Q Specialty Medicines Sales GBP3.2B

29 apr. 2026, 06:05 UTC

Câștiguri

Analysts Saw GSK PLC 1Q Net Profit at GBP1.74B

29 apr. 2026, 06:04 UTC

Câștiguri

Analysts Saw GSK 1Q Adjusted Operating Profit of GBP2.46B

29 apr. 2026, 06:04 UTC

Câștiguri

GSK PLC 1Q Adjusted Operating Profit GBP2.65B

29 apr. 2026, 06:04 UTC

Câștiguri

Analysts Saw GSK PLC Core EPS of 43.3p

29 apr. 2026, 06:04 UTC

Câștiguri

Analysts Saw GSK PLC 1Q Turnover at GBP7.58B

29 apr. 2026, 06:04 UTC

Câștiguri

GSK PLC 1Q Adj EPS 46.50p

29 apr. 2026, 06:01 UTC

Câștiguri

GSK PLC Sees 2026 Adjusted EPS Growth of 7%-9%

29 apr. 2026, 06:01 UTC

Câștiguri

GSK PLC Sees 2026 Adjusted Oper Pft Growth of 7%-9%

29 apr. 2026, 06:01 UTC

Câștiguri

GSK PLC Sees 2026 Turnover Growth of 3%-5%

29 apr. 2026, 06:01 UTC

Câștiguri

GSK PLC Backs 2026 View

29 apr. 2026, 06:00 UTC

Câștiguri

GSK PLC 1Q EPS 42.6p

29 apr. 2026, 06:00 UTC

Câștiguri

GSK PLC 1Q Turnover GBP7.63B

29 apr. 2026, 06:00 UTC

Câștiguri

GSK PLC 1Q Pretax Pft GBP2.14B

29 apr. 2026, 06:00 UTC

Câștiguri

GSK PLC 1Q Oper Pft GBP2.29B

29 apr. 2026, 06:00 UTC

Câștiguri

GSK PLC 1Q Net Pft GBP1.74B

15 apr. 2026, 06:12 UTC

Achiziții, Fuziuni, Preluări

GSK Completes Acquisition of 35Pharma

10 apr. 2026, 10:43 UTC

Market Talk

GSK Could Report Weak General Medicines Results -- Market Talk

GlaxoSmithKline PLC Așteptări

Obiectiv de preț

By TipRanks

8.57% sus

Prognoză pe 12 luni

Medie 2,082.36 GBX  8.57%

Maxim 2,630 GBX

Minim 1,700 GBX

În baza a 14 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruGlaxoSmithKline PLC - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Neutru

14 ratings

4

Cumpărare

7

Păstrare

3

Vânzare

Sentiment

By Acuity

101 / 344 Clasament în Sănătate

Sentimentul știrilor

Evidențe de creștere

Volatilitate

Sub medie

Volumul știrilor (RCV)

Sub medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre GlaxoSmithKline PLC

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development; two strategic collaborations with Relation to advance therapeutics for fibrotic diseases and osteoarthritis; and multi-target strategic alliance with GSK to develop breakthrough treatments for people afflicted with Parkinson's disease; as well as collaboration with Flagship Pioneering to discover novel medicines and vaccines. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.dom.
help-icon Live chat